Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with slapenrich

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Iorio, Francesco ^a,b,e   Garcia Alonso, Luz ^a,e   Brammeld, Jonathan S ^b   Martincorena, Iňigo ^b   Wille, David R ^c,e   McDermott, Ultan ^b   Saez Rodriguez, Julio ^a,d,e  

^a EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e OpenTargets   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISSECTION; DRIVER; HUMAN; MAJOR CLINICAL STUDY; SOMATIC MUTATION; STATISTICS; TUMOR GENE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; GENOMICS; HUMAN GENOME; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION; THEORETICAL MODEL;

TUMOR PROTEIN;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; GENOMICS; HUMANS; MODELS, THEORETICAL; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85046621112     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-25076-6     Document Type: Article

References (73)

1. Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature genetics 45, 1113-1120 (2013).
2. Consortium, T. I. C. G. et al. PERSPECTIVES. Nature 464, 993-998 (2010).
3. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
4. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
5. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
6. Garraway, L. A. & Lander, E. S. Lessons from the Cancer Genome. Cell 153, 17-37 (2013).
7. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
8. Pe'er, D. & Hacohen, N. Principles and strategies for developing network models in cancer. Cell 144, 864-873 (2011).
9. Shi, W. et al. Pathway level alterations rather than mutations in single genes predict response to HER2-Targeted therapies in the neo-ALTTO trial. Annals of Oncology mdw434 (2016).
10. Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nature Methods 10, 1108-1115 (2013).
11. Leiserson, M. D. M. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature genetics 47, 106-114 (2015).
12. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
13. Vogelstein, B. et al. Cancer Genome Landscapes. Science (New York, NY) 339, 1546-1558 (2013).
14. Wendl, M. C. et al. PathScan: A tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics 27, 1595-1602 (2011).
15. Gaffney, S. G. & Townsend, J. P. PathScore: A web tool for identifying altered pathways in cancer data. Bioinformatics (2016).
16. Creixell, P. et al. Pathway and network analysis of cancer genomes. Nature Methods 12, 615-621 (2015).
17. Reimand, J., Arak, T. & Vilo, J. g:Profiler-A web server for functional interpretation of gene lists (2011 update). Nucleic Acids Research 39, W307-W315 (2011).
18. Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC bioinformatics 10, 48 (2009).
19. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4, 44-57 (2008).
20. Wu, D. & Smyth, G. K. Camera: A competitive gene set test accounting for inter-gene correlation. Nucleic Acids Research 40, e133-e133 (2012).
21. Drier, Y., Sheffer, M. & Domany, E. Pathway-based personalized analysis of cancer. Proceedings of the National Academy of Sciences of the United States of America 110, 6388-6393 (2013).
22. Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Research 22, 398-406 (2012).
23. Vandin, F., Upfal, E. & Raphael, B. J. De novo discovery of mutated driver pathways in cancer. Genome Research 22, 375-385 (2012).
24. Schubert, M. & Iorio, F. Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. Pharmacogenomics 15, 1943-1946 (2014).
25. Li, H. T., Zhang, J., Xia, J. & Zheng, C. H. Identification of driver pathways in cancer based on combinatorial patterns of somatic gene mutations. Neoplasma 63, 57-63 (2016).
26. Lu, S. et al. Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets. PLoS computational biology 11, e1004257 (2015).
27. Constantinescu, S., Szczurek, E., Mohammadi, P., Rahnenführer, J. &Beerenwinkel, N. TiMEx: A waiting time model for mutually exclusive cancer alterations. Bioinformatics (2015).
28. Yeang, C. H., McCormick, F. & Levine, A. Combinatorial patterns of somatic gene mutations in cancer. The FASEB Journal 22, 2605-2622 (2008).
29. Youn, A. & Simon, R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics 27, 175-181 (2011).
30. Thomas, R. K. et al. High-Throughput oncogene mutation profiling in human cancer. Nature genetics 39, 347-351 (2007).
31. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Research 44, D457-62 (2016).
32. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545 (2005).
33. Cerami, E. G. et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Research 39, D685-90 (2011).
34. Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell (2016).
35. Knijnenburg, T. A., Bismeijer, T., Wessels, L. F. A. & Shmulevich, I. A multilevel pan-cancer map links gene mutations to cancer hallmarks. Chinese journal of cancer 34, 439-449 (2015).
36. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).
37. Manié, E. et al. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. International Journal of Cancer 138, 891-900 (2016).
38. Walsh, C. S. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecologic oncology 137, 343-350 (2015).
39. Yu, X. et al. Androgen receptor signaling regulates growth of glioblastoma multiforme in men. Tumour biology: The journal of the International Society for Oncodevelopmental Biology and Medicine 36, 967-972 (2015).
40. Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. (2010).
41. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
42. Syed, D. N., Khan, M. I., Shabbir, M. & Mukhtar, H. MicroRNAs in skin response to UV radiation. Current drug targets 14, 1128-1134 (2013).
43. Zhang, X., Wan, G., Berger, F. G., He, X. & Lu, X. The ATM kinase induces microRNA biogenesis in the DNA damage response. Molecular cell 41, 371-383 (2011).
44. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine 372, 2018-2028 (2015).
45. Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine 372, 2521-2532 (2015).
46. Motzer, R. J. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine 373, 1803-1813 (2015).
47. Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine 372, 2509-2520 (2015).
48. Jess, T., Rungoe, C. & Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-Analysis of population-based cohort studies. Clinical gastroenterology and hepatology: The official clinical practice journal of the American Gastroenterological Association 10, 639-645 (2012).
49. West, N. R., McCuaig, S., Franchini, F. & Powrie, F. Emerging cytokine networks in colorectal cancer. Nature reviews. Immunology 15, 615-629 (2015).
50. Lasry, A., Zinger, A. & Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nature immunology 17, 230-240 (2016).
51. Poteet, E. et al. Reversing the Warburg effect as a treatment for glioblastoma. Journal of Biological Chemistry 288, 9153-9164 (2013).
52. Pikor, L., Thu, K., Vucic, E. & Lam, W. The detection and implication of genome instability in cancer. Cancer metastasis reviews 32, 341-352 (2013).
53. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
54. Deryugina, E. I. & Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer metastasis reviews 25, 9-34 (2006).
55. Rabbani, S. A. & Mazar, A. P. The role of the plasminogen activation system in angiogenesis and metastasis. Surgical oncology clinics of North America 10, 393-415 (2001).
56. Kumari, S. & Malla, R. New Insight on the Role of Plasminogen Receptor in Cancer Progression. Cancer growth and metastasis 8, 35-42 (2015).
57. Zarling, J. M. et al. Oncostatin M: A growth regulator produced by differentiated histiocytic lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America 83, 9739-9743 (1986).
58. Tartour, E. et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. British journal of cancer 69, 911-913 (1994).
59. Lacreusette, A. et al. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 26, 881-892 (2007).
60. Caffarel, M. M. & Coleman, N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. The Journal of pathology 232, 386-390 (2014).
61. Faraone, D. et al. Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (New York, NY) 11, 732-742 (2009).
62. Yamazaki, D., Kurisu, S. & Takenawa, T. Regulation of cancer cell motility through actin reorganization. Cancer science 96, 379-386 (2005).
63. Bid, H. K., Roberts, R. D., Manchanda, P. K. & Houghton, P. J. RAC1: An emerging therapeutic option for targeting cancer angiogenesis and metastasis. Molecular Cancer Therapeutics 12, 1925-1934 (2013).
64. Bailey, C. L., Kelly, P. & Casey, P. J. Activation of Rap1 promotes prostate cancer metastasis. Cancer research 69, 4962-4968 (2009).
65. Lee, J.-W., Ryu, Y.-K., Ji, Y.-H., Kang, J. H. & Moon, E.-Y. Hypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1-and Rac1-GTPase activation via the expression of thymosin beta-4. Oncotarget 6, 9820-9833 (2015).
66. Matin, R. N. et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. The Journal of experimental medicine 210, 581-603 (2013).
67. Costanzo, A. et al. TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. FEBS letters 588, 2590-2599 (2014).
68. Brammeld, J. S. et al. Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Research (2017).
69. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America 100, 9440-9445 (2003).
70. Wain, H. M. et al. Guidelines for human gene nomenclature. Genomics 79, 464-470 (2002).
71. Forbes, S. A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Research 43, D805-11 (2015).
72. Gonzalez-Perez, A. & Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucleic Acids Research 40, e169 (2012).
73. Tamborero, D., Gonzalez-Perez, A. & Lopez-Bigas, N. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29, 2238-2244 (2013).